ADVISORY, Oct. 25, 2013 (GLOBE NEWSWIRE) -- What: Aerie Pharmaceuticals [AERI], a clinical-stage pharmaceutical company that focuses on the treatment of glaucoma, will visit the NASDAQ MarketSite in Times Square in celebration of its initial public offering (IPO) which occurred on the NASDAQ Stock Market today, October 25. In honor of the occasion, Vicente Anido, Jr., Ph.D., Chairman and CEO, will ring the Closing Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Friday, October 25, 2013 – 3:45 p.m. to 4:00 p.m. ET Contact : Richard Rubino (908) 470-4320 firstname.lastname@example.org NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ . For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx . Webcast: A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx . Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice. About Aerie Pharmaceuticals [AERI]: Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's lead product candidate, AR-13324, is the first of a new dual-action drug class that was discovered by Aerie scientists. AR-13324 is a once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. Aerie's product candidate PG324 is a fixed combination of dual-action AR-13324 with latanoprost formulated in a single eye drop and is designed to lower intraocular pressure by reducing fluid inflow while also opening both of the eye's fluid drains.